May 16, 2024
|
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
|
May 14, 2024
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
May 7, 2024
|
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
|
May 2, 2024
|
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 1, 2024
|
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
|
Apr 18, 2024
|
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
|
Mar 28, 2024
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Mar 25, 2024
|
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
|
Mar 12, 2024
|
Ardelyx, Inc. Reports Employment Inducement Grants
|
Feb 27, 2024
|
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
|